Which biologic is best for nasal polyps? new study aims to find out
NCT ID NCT06824649
First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 4 times
Summary
This study will compare three FDA-approved biologic drugs (dupilumab, omalizumab, and mepolizumab) in 504 adults with chronic sinusitis and nasal polyps. The goal is to see which drug works best for different patients and whether simple tests can predict who will improve the most. Participants will receive one of the biologics and be followed for changes in quality of life and symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SINUSITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical University of South Carolina
RECRUITINGCharleston, South Carolina, 29425, United States
-
Oregon Health and Science University
RECRUITINGPortland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug that calms inflammation ease chronic sinusitis?
- Can an asthma drug shrink nasal polyps? a major trial seeks answers
- Can a single drug shrink nasal polyps and restore breathing?
- Nanoparticle steroid spray could transform recovery after sinus surgery
- Could a single biologic replace steroid sprays for nasal polyps?
- Withdrawn study sought to understand sinus problems in young cancer survivors